Clinical Trial Update: Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses [Phase 2]

View source ↗

Summary

This completed Phase 2 study updates the long-term safety and efficacy of teriflunomide (HMR1726) in relapsing multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Teriflunomide (teriflunomide)

Snippet

Sponsor: Sanofi | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED